blonanserin hcl

Blonanserin is an antagonist of dopamine-D2 and serotonin-S2.

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Blonanserin-D5 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.

Blonanserin (Standard) is a reference standard for research and analysis in studies involving Blonanserin. Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Blonanserin D8 (Standard) is a reference standard of Blonanserin D8 intended for quantitative analysis, quality control, and related biochemical research applications.

Blonanserin-D5 is a deuterated compound of Blonanserin. Blonanserin (T1180) has a CAS number of 132810-10-7. Blonanserin (T1180) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Blonanserin-D8 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.